Kiora Pharmaceuticals Inc Dossier - Source-backed chat

Kiora Pharmaceuticals Inc

KPRXNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)0.11

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $2.58Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $11.4M

Enterprise Value $4.3M

Shares Outstanding 4.4M diluted

Next Earnings Date6 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Kiora Pharmaceuticals is a clinical-stage biopharmaceutical company uniquely positioned in the orphan retinal disease space. Its lead asset, KIO-301, is a first-in-class molecular photoswitch designed to restore vision in patients with late-stage retinitis pigmentosa, regardless of the underlying genetic mutation. Backed by a strong global licensing partnership with Théa Open Innovation and an exclusive option agreement with Senju Pharmaceutical for Asian rights, Kiora has validated its platform and secured non-dilutive funding. Following a strategic private placement and equity investments in early 2026, the company has extended its cash runway into late 2028, well beyond the anticipated Phase 2 readouts for both KIO-301 (ABACUS-2) and KIO-104 (KLARITY). This robust financial runway, combined with external validation from a publication in Nature Medicine, presents a highly asymmetric risk-reward profile for investors.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets1 analysts · as of 18 Aug 2026

Low · most bearish analyst$12.00

Mean target$12.00

High · most bullish analyst$12.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$1.0015%

The bear case is driven by potential clinical delays or safety concerns in the ABACUS-2 or KLARITY trials, leading to program suspensions. Failure of KIO-301 to show meaningful vision restoration would invalidate the core photoswitch thesis, causing Théa to terminate the partnership and Senju to let its option expire. This would force Kiora to seek highly dilutive financing or restructure its pipeline under severe capital constraints.

Base CaseCentral scenario

$6.0050%

The base case assumes steady clinical execution with Phase 2 data readouts for KIO-104 in H1 2027 and KIO-301 in Q3 2027 meeting safety and efficacy endpoints. The company maintains its cash runway into late 2028 through disciplined spending and routine R&D reimbursements from Théa. The market gradually prices in the clinical progress, aligning the stock closer to consensus analyst targets.

Bull CaseUpside scenario

$10.0035%

The bull case assumes rapid enrollment and highly positive Phase 2 data readouts for both KIO-301 and KIO-104. Positive ABACUS-2 data in Q3 2027 triggers the expansion of the Théa partnership, unlocking significant milestone payments. Concurrently, Senju Pharmaceutical exercises its option for Asian rights, bringing in up to $110 million in development and commercial milestones. KIO-300 successfully transitions from preclinical epilepsy models into clinical development, demonstrating platform versatility beyond ophthalmology.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Validated molecular photoswitch platform (KIO-301) with gene-agnostic potential to restore vision in retinitis pigmentosa, Stargardt disease, and choroideremia.
Strong global partnerships, including a licensing deal with Théa Open Innovation and an option agreement with Senju Pharmaceutical.
Robust cash runway extending into late 2028, funded past critical Phase 2 clinical readouts.
External scientific validation with Phase 1 ABACUS-1 results published in Nature Medicine in April 2026.

Key Investment Risks

High clinical development risk inherent to early-stage ophthalmic therapies.
Dependence on partners (Théa and Senju) for late-stage development, regulatory approval, and commercialization.
Potential for future shareholder dilution, highlighted by the June 2026 approval to increase the equity incentive plan pool by 1.5 million shares.
Historical unprofitability with an accumulated deficit of $156.6 million as of March 31, 2026.

Thesis Invalidation Triggers

Failure of KIO-301 to meet primary efficacy or safety endpoints in the ABACUS-2 Phase 2 trial.
Termination of the global licensing agreement by Théa Open Innovation.
Senju Pharmaceutical deciding not to exercise its option for Asian rights.
Severe clinical trial delays that exhaust the cash runway before topline data readouts.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.